{"id":"https://openalex.org/W52949034","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.8521","title":"A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results","display_name":"A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W52949034","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.8521","mag":"52949034"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.8521","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.8521","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.8521","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078601045","display_name":"Jeff Zonder","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. A. Zonder","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103408877","display_name":"John J. Crowley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. J. Crowley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065094159","display_name":"Vanessa Bolejack","orcid":"https://orcid.org/0000-0003-2118-8500","observed_orcids":["https://orcid.org/0000-0003-2118-8500"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Bolejack","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"M. A. Hussein","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. A. Hussein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046291236","display_name":"D. F. Moore","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. F. Moore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066263005","display_name":"Brock F. Whittenberger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. F. Whittenberger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055027283","display_name":"Muneer Hyder Abidi","orcid":"https://orcid.org/0000-0002-9936-6031","observed_orcids":["https://orcid.org/0000-0002-9936-6031"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. H. Abidi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026109406","display_name":"Brian G.M. Durie","orcid":"https://orcid.org/0000-0002-9883-3769","observed_orcids":["https://orcid.org/0000-0002-9883-3769"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. G. Durie","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5000879635","display_name":"Bart Barlogie","orcid":"https://orcid.org/0000-0001-6116-1017","observed_orcids":["https://orcid.org/0000-0001-6116-1017"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Barlogie","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"8521","last_page":"8521"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/newly-diagnosed-multiple-myeloma","display_name":"newly diagnosed multiple myeloma","score":0.9359999895095825},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9580000042915344},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.996999979019165},{"id":"https://openalex.org/keywords/chromosomal-abnormalities","display_name":"chromosomal abnormalities","score":0.8629999756813049},{"id":"https://openalex.org/keywords/chromosome-13-deletion","display_name":"chromosome 13 deletion","score":0.8140000104904175},{"id":"https://openalex.org/keywords/chromosome-17-deletion","display_name":"chromosome 17 deletion","score":1.0},{"id":"https://openalex.org/keywords/karyotypic-abnormalities","display_name":"karyotype abnormalities","score":0.9120000004768372},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9769999980926514},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6830000281333923},{"id":"https://openalex.org/keywords/lenalidomide-maintenance","display_name":"lenalidomide maintenance","score":0.6039999723434448},{"id":"https://openalex.org/keywords/high-risk-cytogenetics","display_name":"high-risk cytogenetics","score":0.625},{"id":"https://openalex.org/keywords/aspirin","display_name":"aspirin","score":0.3619999885559082}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.74086594581604},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.6898004412651062},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6611109972000122},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5731357932090759},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.5423501133918762},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.44980916380882263},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44799864292144775}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.8521","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.8521","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.8521","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2979863687","https://openalex.org/W4389246844","https://openalex.org/W2951778659","https://openalex.org/W2582098938","https://openalex.org/W4232496617","https://openalex.org/W2546416649","https://openalex.org/W2979329362","https://openalex.org/W2002605588","https://openalex.org/W2946062734","https://openalex.org/W2275479821"],"abstract_inverted_index":{"8521":[0],"Background:":[1],"We":[2,49],"recently":[3],"reported":[4],"superior":[5],"1-yr":[6,71,247,273,282],"prog.":[7],"free":[8],"survival":[9,75],"(PFS)":[10],"for":[11,134,151,156,207,286,335,378,386],"pts":[12,39,86,174,220,232,242,263,287,307],"with":[13,16,28,42,87,264,270,293,308,312,349,352],"NDMM":[14,88,309],"treated":[15,351],"LD":[17,41,131,238,244,289,311,353],"vs":[18,256,295],"D":[19,110,121,234,268,363],"alone.":[20,364],"High-risk":[21],"cytogenetic":[22],"abnormalities":[23],"(HRCA)":[24],"confer":[25],"poor":[26],"prognosis":[27],"standard":[29],"therapies,":[30],"including":[31],"high":[32],"dose":[33],"melphalan.":[34],"It":[35],"is":[36],"unknown":[37],"if":[38],"on":[40,70,137,189,221,225,233,237,243,267,288,310,362],"HRCA":[43,59,186,294,300,324],"will":[44,388],"also":[45],"have":[46],"inferior":[47],"results.":[48,83],"prospectively":[50],"examined":[51],"the":[52,342,346],"impact":[53,182],"of":[54,63,96,104,158,173,183,228,277,345,367],"abnormal":[55],"karyotype":[56],"(AK)":[57],"and":[58,73,124,154,161,171,185,191,202,209,223,235,249,253,259,275,279,284,297,317,357,370,381],"(defined":[60],"as":[61,77,79,107,325,373,375],"deletion":[62],"chromosomes":[64,159],"13":[65,160],"and/or":[66],"17":[67],"by":[68,167,187,195],"FISH)":[69],"PFS":[72,190,248,274,283,316,356],"overall":[74,81],"(OS),":[76],"well":[78,374],"updated":[80],"study":[82,177,329],"Methods:":[84],"198":[85],"were":[89,179,205,214,251,290],"randomized":[90],"to":[91,130,320,333,360],"L":[92],"25":[93],"mg/day":[94],"(28":[95],"35":[97],"days":[98,106],"x":[99],"3":[100],"cycles,":[101],"then":[102],"21":[103],"28":[105],"maintenance)":[108,119],"+":[109,127],"(40":[111],"mg":[112],"d1\u20134,":[113,117],"9\u201312,":[114],"17\u201320":[115],"induction;":[116],"15\u201318":[118],"or":[120,396,399],"(same":[122],"induction":[123],"maintenance":[125],"schedules)":[126],"placebo.":[128],"Cross-over":[129],"was":[132,142,193],"allowed":[133],"progressive":[135],"disease":[136],"D.":[138],"Aspirin":[139],"325":[140],"mg/d":[141],"mandated.":[143],"Pts":[144,266,348],"had":[145,239,272,314,354],"a":[146],"baseline":[147,200],"bone":[148],"marrow":[149],"aspirate":[150],"karyotypic":[152,369],"analysis":[153],"FISH":[155,188,203,371],"deletions":[157],"17.":[162],"The":[163,181],"response":[164],"rate":[165],"(RR)":[166],"IMWG":[168],"criteria,":[169],"PFS,":[170,379],"OS":[172,192,250,276,285,318,358],"in":[175,216,262,327],"each":[176],"arm":[178],"updated.":[180],"AK":[184,213,271,313,350],"assessed":[194],"log-rank":[196],"analysis.":[197,347],"Results:":[198],"Informative":[199],"karyotypes":[201],"results":[204],"available":[206],"103":[208],"80":[210],"pts,":[211],"respectively.":[212],"seen":[215],"10/52":[217],"samples":[218,230],"from":[219,231],"D,":[222],"11/51":[224],"LD.":[226],"Twelve":[227],"45":[229],"8/35":[236],"HRCA.":[240],"For":[241],"without":[245,299,322],"AK,":[246],"86%":[252],"97%":[254],"respectively,":[255],"55%":[257],"(p=0.13)":[258],"82%":[260],"(p=0.02)":[261],"AK.":[265,323],"alone":[269],"33%":[278],"77%":[280],"(p=NS).":[281,301],"both":[291],"100%":[292],"73%":[296],"92%":[298],"Conclusions:":[302],"In":[303],"this":[304,328,336],"sub-group":[305],"analysis,":[306],"lower":[315],"compared":[319,359],"those":[321,361],"defined":[326],"did":[330],"not":[331],"seem":[332],"account":[334],"difference,":[337],"but":[338],"sample":[339],"size":[340],"limited":[341],"statistical":[343],"power":[344],"higher":[355],"Further":[365],"characterization":[366],"observed":[368],"abnormalities,":[372],"extended":[376],"follow-up":[377],"OS,":[380],"RR":[382],"(including":[383],"\u2265VGPR":[384],"rates)":[385],"S0232":[387],"be":[389],"presented":[390],"at":[391],"ASCO.":[392],"Author":[393],"Disclosure":[394],"Employment":[395],"Leadership":[397],"Consultant":[398],"Advisory":[400],"Role":[401],"Stock":[402],"Ownership":[403],"Honoraria":[404],"Research":[405],"Expert":[406],"Testimony":[407],"Other":[408],"Remuneration":[409],"Celgene,":[410,412],"Millennium":[411,413]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}